Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARSCoV2 Infection: A Review of Current Evidence". | Drugs;82(3): 353-354, 2022 02. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARSCoV2 Infection: A Review of Current Evidence".

Lenze, Eric J; Reiersen, Angela M; Facente, Shelley N.

Affiliation

Lenze EJ; Washington University in St. Louis, St. Louis, Missouri, USA.
Reiersen AM; Washington University in St. Louis, St. Louis, Missouri, USA.
Facente SN; University of California, Berkeley, 2121 Berkeley Way West, 5th Floor, Berkeley, CA, 94720, USA. sfacente@berkeley.edu.

Drugs ; 82(3): 353-354, 2022 02.

Article in En | MEDLINE | ID: mdl-35150436

Subject(s)

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Fluvoxamine / COVID-19 Drug Treatment Limits: Humans Language: En Journal: Drugs Year: 2022 Document type: Article Affiliation country: Estados Unidos Country of publication: Nueva Zelanda

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Fluvoxamine / COVID-19 Drug Treatment Limits: Humans Language: En Journal: Drugs Year: 2022 Document type: Article Affiliation country: Estados Unidos Country of publication: Nueva Zelanda